Brief: Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs
07/04/2026 03:15
April 7 (Reuters) - Mayne Pharma Group Ltd MYX.AX: MYX EXPECTS NO MATERIAL IMPACT FROM US S232 TARIFFS ENTIRE US DERMATOLOGY GENERICS PORTFOLIO EXPECTED TO BE EXEMPT FROM TARIFFS UNDER PROCLAMATION NO MATERIAL IMPACT EXPECTED FOR MAYNE PHARMA'S WOMEN'S HEALTH PORTFOLIO FROM US S232 TARIFFS SEVERAL OF COMPANY'S BRANDED DERMATOLOGY PRODUCTS MAY BE SUBJECT TO NEW SECTION 232 TARIFFS MINIMAL IMPACT EXPECTED IN SALISBURY, SOUTH AUSTRALIA MANUFACTURING FACILITY AS MOST EXPORT PRODUCTS TO US ARE GENERIC PRODUCTS Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)